Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,427 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Relationships among Postprandial Plasma Active GLP-1 and GIP Excursions, Skeletal Muscle Mass, and Body Fat Mass in Patients with Type 2 Diabetes Treated with Either Miglitol, Sitagliptin, or Their Combination: A Secondary Analysis of the MASTER Study.
Sato M, Fujita H, Yokoyama H, Mikada A, Horikawa Y, Takahashi Y, Yamada Y, Waki H, Narita T. Sato M, et al. Among authors: yokoyama h. J Clin Med. 2023 Apr 24;12(9):3104. doi: 10.3390/jcm12093104. J Clin Med. 2023. PMID: 37176545 Free PMC article.
Improvement of β-Cell Function After Switching From DPP-4 Inhibitors to Oral Semaglutide: SWITCH-SEMA2 Post Hoc Analysis.
Nomoto H, Furusawa S, Yokoyama H, Suzuki Y, Izumihara R, Oe Y, Takahashi K, Miya A, Kameda H, Cho KY, Takeuchi J, Kurihara Y, Nakamura A, Atsumi T. Nomoto H, et al. Among authors: yokoyama h. J Clin Endocrinol Metab. 2024 May 2:dgae213. doi: 10.1210/clinem/dgae213. Online ahead of print. J Clin Endocrinol Metab. 2024. PMID: 38695547
Improved time in range and postprandial hyperglycemia with canagliflozin in combination with teneligliptin: Secondary analyses of the CALMER study.
Cho KY, Nomoto H, Nakamura A, Kawata S, Sugawara H, Takeuchi J, Nagai S, Omori K, Tsuchida K, Miya A, Shigesawa I, Tsuchida K, Yanagiya S, Kameda H, Yokoyama H, Taneda S, Kurihara Y, Aoki S, Nishimoto N, Atsumi T, Miyoshi H. Cho KY, et al. Among authors: yokoyama h. J Diabetes Investig. 2021 Aug;12(8):1417-1424. doi: 10.1111/jdi.13498. Epub 2021 Feb 5. J Diabetes Investig. 2021. PMID: 33421309 Free PMC article. Clinical Trial.
Effects of omarigliptin on glucose variability and oxidative stress in type 2 diabetes patients: A prospective study.
Ohara M, Nagaike H, Fujikawa T, Kohata Y, Ogawa M, Omachi T, Sasajima R, Chiba H, Ara T, Sugawara A, Hiromura M, Terasaki M, Mori Y, Fukui T, Hirano T, Yokoyama H, Yamagishi SI. Ohara M, et al. Among authors: yokoyama h. Diabetes Res Clin Pract. 2021 Sep;179:108999. doi: 10.1016/j.diabres.2021.108999. Epub 2021 Aug 12. Diabetes Res Clin Pract. 2021. PMID: 34390762 Clinical Trial.
Favourable effect of the sodium-glucose co-transporter-2 inhibitor canagliflozin plus the dipeptidyl peptidase-4 inhibitor teneligliptin in combination on glycaemic fluctuation: An open-label, prospective, randomized, parallel-group comparison trial (the CALMER study).
Cho KY, Nomoto H, Nakamura A, Kawata S, Sugawara H, Takeuchi J, Nagai S, Tsuchida K, Omori K, Yokoyama H, Manda N, Kurihara Y, Aoki S, Atsumi T, Miyoshi H. Cho KY, et al. Among authors: yokoyama h. Diabetes Obes Metab. 2020 Mar;22(3):458-462. doi: 10.1111/dom.13879. Epub 2019 Oct 13. Diabetes Obes Metab. 2020. PMID: 31486230 Free PMC article. Clinical Trial.
Receptor-Mediated Bioassay Reflects Dynamic Change of Glucose-Dependent Insulinotropic Polypeptide by Dipeptidyl Peptidase 4 Inhibitor Treatment in Subjects With Type 2 Diabetes.
Yanagimachi T, Fujita Y, Takeda Y, Honjo J, Yokoyama H, Haneda M. Yanagimachi T, et al. Among authors: yokoyama h. Front Endocrinol (Lausanne). 2020 Apr 24;11:214. doi: 10.3389/fendo.2020.00214. eCollection 2020. Front Endocrinol (Lausanne). 2020. PMID: 32390941 Free PMC article.
Tofogliflozin does not delay progression of carotid atherosclerosis in patients with type 2 diabetes: a prospective, randomized, open-label, parallel-group comparative study.
Katakami N, Mita T, Yoshii H, Shiraiwa T, Yasuda T, Okada Y, Torimoto K, Umayahara Y, Kaneto H, Osonoi T, Yamamoto T, Kuribayashi N, Maeda K, Yokoyama H, Kosugi K, Ohtoshi K, Hayashi I, Sumitani S, Tsugawa M, Ryomoto K, Taki H, Nakamura T, Kawashima S, Sato Y, Watada H, Shimomura I; UTOPIA study investigators. Katakami N, et al. Among authors: yokoyama h. Cardiovasc Diabetol. 2020 Jul 9;19(1):110. doi: 10.1186/s12933-020-01079-4. Cardiovasc Diabetol. 2020. PMID: 32646498 Free PMC article. Clinical Trial.
Impact of endogenous insulin secretion on the improvement of glucose variability in Japanese patients with type 2 diabetes treated with canagliflozin plus teneligliptin.
Miya A, Nakamura A, Cho KY, Kawata S, Nomoto H, Nagai S, Sugawara H, Taneda S, Tsuchida K, Omori K, Yokoyama H, Takeuchi J, Aoki S, Kurihara Y, Atsumi T, Miyoshi H. Miya A, et al. Among authors: yokoyama h. J Diabetes Investig. 2021 Aug;12(8):1395-1399. doi: 10.1111/jdi.13479. Epub 2021 Jan 21. J Diabetes Investig. 2021. PMID: 33325645 Free PMC article. Clinical Trial.
Effect of tofogliflozin on arterial stiffness in patients with type 2 diabetes: prespecified sub-analysis of the prospective, randomized, open-label, parallel-group comparative UTOPIA trial.
Katakami N, Mita T, Yoshii H, Shiraiwa T, Yasuda T, Okada Y, Torimoto K, Umayahara Y, Kaneto H, Osonoi T, Yamamoto T, Kuribayashi N, Maeda K, Yokoyama H, Kosugi K, Ohtoshi K, Hayashi I, Sumitani S, Tsugawa M, Ryomoto K, Taki H, Nakamura T, Kawashima S, Sato Y, Watada H, Shimomura I; UTOPIA study investigators. Katakami N, et al. Among authors: yokoyama h. Cardiovasc Diabetol. 2021 Jan 4;20(1):4. doi: 10.1186/s12933-020-01206-1. Cardiovasc Diabetol. 2021. PMID: 33397376 Free PMC article. Clinical Trial.
The renoprotective effect of once-weekly GLP-1 receptor agonist dulaglutide on progression of nephropathy in Japanese patients with type 2 diabetes and moderate to severe chronic kidney disease (JDDM67).
Tsuchida KI, Taneda S, Yokota I, Okada K, Kurihara Y, Yokoyama H, Iwamoto M, Yamazaki K, Ishigaki Y, Manda N, Maegawa H; Japan Diabetes Clinical Data Management Study Group (JDDM study group). Tsuchida KI, et al. Among authors: yokoyama h. J Diabetes Investig. 2022 Nov;13(11):1834-1841. doi: 10.1111/jdi.13877. Epub 2022 Jul 5. J Diabetes Investig. 2022. PMID: 35735780 Free PMC article.
2,427 results